Page 202 - 2022_03-Haematologica-web

Letters to the Editor
BNT162b1 elicits human antibody and TH1 T cell responses.
Nature. 2020;586(7830):594-599.
9. Candon S, Guerrot D, Drouot L, et al. T cell and antibody
responses to SARS-CoV-2: Experience from a French transplanta- tion and hemodialysis center during the COVID-19 pandemic. Am J Transplant. 2021;21(2):854-863.
10. Bonelli MM, Mrak D, Perkmann T, Haslacher H, Aletaha D. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. Ann Rheum Dis. 2021;80(10):1355-1356.
11. Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T Cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158-168.e14.
12. Benotmane I, Gautier G, Perrin P, et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA. 2021;326(11):1063-1065.
13. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ trans- plant recipients. N Engl J Med. 2021;385(7):661-662.
14. Redjoul R, Le Bouter A, Parinet V, Fourati S, Maury S. Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT. Lancet Haematol. 2021;8(10):e681-e683.
15. Tenbusch M, Schumacher S, Vogel E, et al. Heterologous prime- boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect Dis. 2021;21(9):1212-1213.
758
haematologica | 2022; 107(3)